Management of Hypertension in Pregnancy with Multiple Comorbidities

Immediate Blood Pressure Management

The European Society of Cardiology recommends initiating treatment at BP ≥140/90 mmHg for pregnant women with any hypertension, with a target blood pressure of 110-135/85 mmHg to reduce maternal risk while maintaining adequate uteroplacental perfusion 1, 2, 3
First-line oral agents for hypertension in pregnancy include methyldopa, labetalol, or long-acting nifedipine, with labetalol being an ideal choice for long-term management of supraventricular arrhythmias and hypertension in pregnancy 4, 5, 6

The patient should continue vitamin D supplementation, as correcting deficiency is important for maternal and fetal bone health 7

Weekly blood pressure monitoring is essential until stable on new antihypertensive regimen, with assessment for preeclampsia symptoms at each visit 1, 3
Urine protein assessment (24-hour collection or protein-to-creatinine ratio) should be performed to evaluate for preeclampsia 1, 3

If severe hypertension develops (≥170/110 mmHg), immediate hospitalization is required with IV labetalol, oral nifedipine, or oral methyldopa 1, 2, 3

The American College of Cardiology recommends monitoring blood pressure for 72 hours in hospital and 7-10 days postpartum, with counseling on increased lifetime cardiovascular risk 5, 6
Women with gestational hypertension have a 4-fold increased risk of future hypertension and 2-fold increased risk of ischemic heart disease, and should undergo annual cardiovascular risk assessment lifelong 1, 2, 3

The European Society of Cardiology recommends avoiding ACE inhibitors, ARBs, direct renin inhibitors, or mineralocorticoid receptor antagonists due to fetotoxicity 1, 5, 7
Atenolol should be avoided, as it is specifically contraindicated for any arrhythmia or hypertension in pregnancy 4